A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

INTRODUCTION: A combination of cetuximab and sorafenib in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) were assessed for potential benefit. MATERIAL AND METHODS: In a randomized phase II study, R/M HNSCC patients were treated with cetuximab 400mg/m(2)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oral Oncol
Auteurs principaux: Gilbert, Jill, Schell, Michael J., Zhao, Xiuhua, Murphy, Barbara, Tanvetyanon, Tawee, Leon, Marino E., Hayes, D. Neil, Haigentz, Missak, Saba, Nabil, Nieva, Jorge, Bishop, Justin, Sidransky, David, Ravi, Rajani, Bedi, Atul, Chung, Christine H.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459134/
https://ncbi.nlm.nih.gov/pubmed/25593015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2014.12.011
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires